DUBLIN--(http://www.researchandmarkets.com/research/dpmcng/fibromyalgia) has announced the addition of the "Fibromyalgia Therapeutics - Global Strategic Business Report" report to their offering.)--Research and Markets (
“Fibromyalgia Therapeutics - Global Strategic Business Report”
This report analyzes the worldwide markets for Fibromyalgia Therapeutics in US$ Million. The report provides separate comprehensive analytics for the US, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets.
The report profiles 26 companies including many key and niche players such as:
- Boehringer Ingelheim GmbH
- Chelsea Therapeutics Inc.
- Claire Ellen Products Inc.
- Eli Lilly and Company
- Forest Laboratories Inc.
- Impax Laboratories Inc.
- Meda AB
- Pfizer Inc.
- Pierre Fabre Médicament
- Synthetic Biologics Inc.
Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.
Total Companies Profiled: 26 (including Divisions/Subsidiaries - 31)
The United States (18)
- France (1)
- Germany (1)
- Rest of Europe (3)
Asia-Pacific (Excluding Japan) (1)
For more information visit http://www.researchandmarkets.com/research/dpmcng/fibromyalgia